4/5
04:01 pm
atra
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/5
02:08 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/1
11:03 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Stifel Nicolaus from $4.80 to $2.30. They now have a "hold" rating on the stock.
Low
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Stifel Nicolaus from $4.80 to $2.30. They now have a "hold" rating on the stock.
3/28
08:40 am
atra
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress [Yahoo! Finance]
Low
Report
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress [Yahoo! Finance]
3/28
08:30 am
atra
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Low
Report
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
3/28
02:08 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/26
08:12 am
atra
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline [Yahoo! Finance]
Low
Report
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline [Yahoo! Finance]
3/18
11:06 pm
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/29
09:19 am
atra
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy [Yahoo! Finance]
High
Report
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy [Yahoo! Finance]
2/29
09:05 am
atra
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
High
Report
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
2/28
04:30 pm
atra
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Low
Report
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
2/23
05:47 am
atra
Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies [Yahoo! Finance]
Medium
Report
Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies [Yahoo! Finance]
2/14
09:23 am
atra
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis [Yahoo! Finance]
Medium
Report
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis [Yahoo! Finance]
2/14
09:00 am
atra
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Low
Report
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
2/3
09:23 am
atra
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain [Yahoo! Finance]
High
Report
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain [Yahoo! Finance]
2/1
02:25 am
atra
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
High
Report
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
1/31
06:36 pm
atra
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology [Yahoo! Finance]
High
Report
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology [Yahoo! Finance]
1/31
06:30 pm
atra
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
High
Report
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology